Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Clin Chest Med. 2010 Mar;31(1):117-26, Table of Contents. doi: 10.1016/j.ccm.2009.08.001.
Lung volume reduction surgery has proven benefits in emphysema. However, high postoperative morbidity and stringent selection criteria for suitable candidates are limitations in clinical practice. Endoscopic approaches to lung volume reduction have used a range of different techniques such as endobronchial blockers, airway bypass, endobronchial valves, biologic sealants, and airway implants to address the limitations of surgery. The underlying physiologic mechanisms of endoscopic modalities vary, and homogeneous and heterogeneous emphysema are targeted. Currently available data on efficacy of bronchoscopic lung volume reduction are not consistently conclusive, and subjective benefit in dyspnea scores is a more frequent finding than improvements on spirometry or exercise tolerance. The safety data are more promising, with rare procedure-related mortality, fewer complications than lung volume reduction surgery, and short hospital length of stay. The field of bronchoscopic lung volume reduction continues to evolve as ongoing prospective randomized trials aim to clarify the efficacy data from earlier feasibility and safety studies.
肺减容术已被证实对肺气肿有益。然而,高术后发病率和严格的适合人选选择标准是临床实践中的局限性。内镜肺减容术采用了一系列不同的技术,如支气管内阻塞物、气道旁路、支气管内瓣膜、生物密封剂和气道植入物,以解决手术的局限性。内镜方法的潜在生理机制不同,针对的是同质和异质肺气肿。目前关于支气管镜肺减容术疗效的数据并不一致,呼吸困难评分的主观改善比肺活量或运动耐量的改善更为常见。安全性数据更有希望,与肺减容手术相比,手术相关死亡率较低,并发症较少,住院时间较短。随着正在进行的前瞻性随机试验旨在澄清早期可行性和安全性研究的疗效数据,支气管镜肺减容术领域仍在不断发展。